three-year update from the checkmate 227 clinical trial for advanced nsclc
Published 4 years ago • 827 plays • Length 17:08Download video MP4
Download video MP3
Similar videos
-
6:51
researcher comment: three-year data from checkmate 227 | suresh ramalingam
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
3:45
asco 2020 data update: checkmate 227
-
6:07
interpreting the results of checkmate-227 in nsclc
-
2:26
checkmate 227 update
-
2:33
checkmate 227: chemo-free nsclc treatment
-
2:17
dr. borghaei on the checkmate-227 trial in nsclc
-
4:34
endometrial cancer uterus fda approved treatment - dr robert debernardo, md
-
3:04
checkmate 227: final analysis for the non small cell lung cancer trial
-
1:29
dr. kelly on the toxicity profile in checkmate-227 in nsclc
-
1:42
dr. patel on checkmate-227 results in advanced nsclc
-
0:50
checkmate 227 induced manageable toxicities with immunotherapy combination in nsclc
-
5:51
checkmate-227 and the role of tmb in nsclc
-
6:04
checkmate 227: tmb versus pd-l1 in advanced-stage nsclc
-
2:21
expert comment: the checkmate 227 study | sanjay popat
-
5:51
nsclc: use of tmb in checkmate-227
-
5:13
checkmate-227 regimen safety profile
-
2:08
dr. porter on the 3-year follow-up data from the checkmate-9la trial in nsclc
-
10:46
the checkmate 9la trial for stage iv/recurrent non-small cell lung cancer